Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$1.2.

  • Regenxbio's EPS (Basic) fell 256.41% to -$1.2 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year increase of 3107.57%. This contributed to the annual value of -$4.59 for FY2024, which is 2386.48% up from last year.
  • As of Q3 2025, Regenxbio's EPS (Basic) stood at -$1.2, which was down 256.41% from -$1.38 recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's EPS (Basic) peaked at $6.93 during Q4 2021, and registered a low of -$1786.6 during Q1 2022.
  • In the last 5 years, Regenxbio's EPS (Basic) had a median value of -$1.39 in 2022 and averaged -$312.3.
  • Over the last 5 years, Regenxbio's EPS (Basic) had its largest YoY gain of 65858.17% in 2021, and its largest YoY loss of 14952530.5% in 2021.
  • Quarter analysis of 5 years shows Regenxbio's EPS (Basic) stood at $6.93 in 2021, then plummeted by 120.06% to -$1.39 in 2022, then decreased by 3.7% to -$1.44 in 2023, then grew by 28.16% to -$1.04 in 2024, then decreased by 15.88% to -$1.2 in 2025.
  • Its last three reported values are -$1.2 in Q3 2025, -$1.38 for Q2 2025, and $0.12 during Q1 2025.